4 recruiting, 2 terminated, 1 active not recruiting, 1 completed. 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 4, Terminated 2, Active not recruiting 1, Completed 1, Suspended 1, Withdrawn 1 |
Follow Erwinase: new trials by email Literature Review of Erwinase trials Research Report on Erwinase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 461 | 2020-12-17 | 2026-11-12 |
| Ma-Spore ALL 2020 Study Prednisolone, Dexamethasone, Vincristine - B Lymphoblastic Leukemia | Phase 2 | Recruiting | National University Hospital, Singapore | 500 | 2020-03-04 | 2024-03-28 |
| AflacLL1901 (CHOA-AML) Cytarabine, Daunorubicin, Erwinase - Acute Myeloid Leukemia, AML, Childhood | Phase 2 | Terminated | Emory University | 8 | 2020-01-24 | 2022-06-15 |
| Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Fludarabine, Cytarabine, Erwinase - Hematologic Malignancy | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2018-05-01 | 2018-06-26 | |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 2 | Active not recruiting | Children's Oncology Group | 80 | 2017-06-19 | 2026-10-01 |
| Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Bortezomib, Vorinostat, Mitoxantrone - Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | St. Jude Children's Research Hospital | 12 | 2015-04-14 | 2018-03-07 |
| Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma Kidrolase, Methotrexate, Dexamethasone - Lymphoma, Non-Hodgkin | Phase 2 | Completed | University Hospital, Limoges | 40 | 2006-02-01 | 2013-02-28 |
Burkitt Lymphoma (6) · Leukemia, Biphenotypic, Acute (3) · Leukemia, Myeloid, Acute (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Lymphoma (2) · Down Syndrome (1) · Hematologic Neoplasms (1) · Leukemia, Prolymphocytic (1) · Lymphoma, B-Cell (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Non-Hodgkin (1) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
National Cancer Institute (NCI) (2) · Children's Oncology Group (1) · City of Hope Medical Center (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · National University Hospital, Singapore (1) · St. Jude Children's Research Hospital (1) · University Hospital, Limoges (1) · University of Washington (1)
United States (7) · Puerto Rico (3) · Australia (1) · Canada (1) · France (1) · Malaysia (1) · Singapore (1)
Allen Eng Juh Yeoh, MBBS (1) · Erin H Breese (1) · Himalee Sabnis, MD (1) · Ibrahim Aldoss (1) · Maureen M O'Brien (1) · Ryan D. Cassaday, MD (1) · Stacy L Cooper (1) · Tanja A. Gruber, MD, PhD (1) · Tapan Kadia, MD (1)
PMID 35622074, PMID 41671463, PMID 21123825, PMID 32683126, PMID 35007127
U10CA180886 (3), 2019 (1), P30CA033572 (1)